Protara Therapeutics, Inc. 8-K Filing

Ticker: TARA · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1359931

Protara Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyProtara Therapeutics, Inc. (TARA)
Form Type8-K
Filed DateDec 3, 2025
Pages5
Reading Time6 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Protara Therapeutics, Inc. (ticker: TARA) to the SEC on Dec 3, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Global Ma).

How long is this filing?

Protara Therapeutics, Inc.'s 8-K filing is 5 pages with approximately 1,594 words. Estimated reading time is 6 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,594 words · 6 min read · ~5 pages · Grade level 13.5 · Accepted 2025-12-03 08:08:52

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Global Ma

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 3, 2025, Protara Therapeutics, Inc. (the "Company" or "Protara") posted an investor presentation (the "Investor Presentation") to the "Investors—Events and Presentations" section of the Company's website and posted a press release (the "Press Release") to the "Investors—News—Press Releases" section of the Company's website. The Investor Presentation and Press Release will be used in connection with a conference call and webcast on December 3, 2025, at 8:30 a.m. ET, to announce updated interim data from the ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS ( Ta/T1) non-muscle invasive bladder cancer ("NMIBC"). Copies of the Investor Presentation and Press Release are attached as Exhibit 99.1 and Exhibit 99.2, respectively. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. Updated Interim Results On December 4, 2025, the Company presented updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS ( Ta/T1) NMIBC at a poster session at the 2025 Annual Meeting of the Society of Urologic Oncology (SUO) Conference, reporting positive results that continue to support TARA-002's potential as a mainstay in the NMIBC treatment landscape and demonstrating meaningful and durable activity in Bacillus Calmette-Gurin ("BCG")-Nave NMIBC patients. A copy of the poster, which has been published to the "Investors—Events and Presentations" section of the Company's website, is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference. The dataset includes 31 BCG-Nave patients who received at least 1 dose of TARA-002; 29 patients completed at least one response assessment and were evaluable for efficacy as of a November 7, 2025 data cutoff. Patients received an induction course of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months. Re-induction was permitted for eligible patients with residual CIS and/or recurrent high-grade Ta disease. Complete response ("CR") rates at the six months and 12 months landmark time points include all participants who were either evaluable at that time point or had experienced disease progression or treatment failure prior to the scheduled visit. The CR rate at any time was 72% (21/29). The CR rate was 69% (18/26) at six months and 50% (7/14) at 12 months. Among initial responders, 88% (14/16) maintained their response through six months and 100% (3/3) through 12 months. Re-induction therapy successfully salvaged most initial non-responders, resulting in high conversion rates and durable responses: 80% (4/5) of re-induced patients converted to a CR at 6 months, and 100% (4/4) of those responders maintained thei

Forward-Looking Statements

Forward-Looking Statements that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara's business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including the timing of any particular phases of such trials and the timing of the announcement of any data produced during such trials or phases thereof; statements related to expectations regarding interactions with the U.S. Food and Drug Administration (FDA); Protara's financial position; statements regarding the anticipated safety or efficacy of Protara's product candidates; and Protara's outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara's financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara's development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regula

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Investor Presentation, dated December 3, 2025. 99.2 Press Release, dated December 3, 2025. 99.3 Poster Presentation, dated December 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 3, 2025 Protara Therapeutics, Inc. By: /s/ Patrick Fabbio Patrick Fabbio Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.